HBY 097 + zidovudine

HBY 097 + zidovudine is an experimental combination therapy for HIV-1 that includes **HBY 097**, a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) of the quinoxaline class, and **zidovudine** (also known as AZT or ZDV), a nucleoside reverse transcriptase inhibitor (NRTI). HBY 097 acts by binding to and inhibiting the HIV-1 reverse transcriptase enzyme, thereby preventing viral RNA replication. Zidovudine is a thymidine analog that also inhibits reverse transcriptase, terminating the viral DNA chain. This combination showed pronounced acute suppression of HIV-1 replication in clinical studies, with combination therapy achieving significantly greater reductions in viral load than monotherapy[1]. The dual mechanism targets HIV-1 at the enzyme level via two distinct sites, reducing the likelihood of resistance development and improving antiviral efficacy. HBY 097 was studied in phase II trials in HIV-1-infected patients; development of resistance via the K103N mutation was less in combination therapy[1]. Zidovudine is a well-established antiretroviral for HIV-1 treatment and prevention, not commonly used as monotherapy[2][4].

Other names

azidothymidineAZTZDV